<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.jnrbm.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Journal of Negative Results in BioMedicine - Most accessed articles</title>
        <link>http://www.jnrbm.com</link>
        <description>The most accessed research articles published by Journal of Negative Results in BioMedicine</description>
        <dc:date>2012-05-10T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/5/1/17" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/11/1/11" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/11/1/10" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/5/1/1" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/11/1/1" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/11/1/12" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/5/1/16" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/9/1/8" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/11/1/7" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/8/1/3" />
                            </rdf:Seq>
        </items>
                 <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.jnrbm.com/content/5/1/17">
        <title>A critique of the WHO TobReg&apos;s &quot;Advisory Note&quot; report entitled: &quot;Waterpipe tobacco smoking: health effects, research needs and recommended actions by regulators&quot;</title>
        <description>Background and aimThe World Health Organisation Study Group on Tobacco Product Regulation (TobReg) has issued in 2005 an &quot;Advisory Note&quot; entitled: &quot;Waterpipe Tobacco Smoking: Health Effects, Research Needs and Recommended Actions by Regulators&quot;. &quot;Waterpipe&quot; smoking is now considered a global public health threat and the corresponding artefact is actually known in the world under three main terms: hookah, narghile and shisha. This important report, the first ever prepared by WHO on the subject, poses two major problems. On one hand, its bibliographical references dismiss world chief relevant studies. On the other, it contains a certain number of errors of many orders: biomedical, sociological, anthropological and historical. The purpose of the present study is to highlight, one by one, where these weaknesses and errors lie and show how this official report can be considerably improved.
Results:
We realise that widely advertised early anthropological studies were not taken into consideration whereas they shed a substantial light on this peculiar form of smoking and help understanding its high complexity. As for concrete errors to be found in this report, they deal with the chemistry of smoke, health-related effects, smoking patterns, description and history of the artefact and its use, gender and underage use aspects, prevention and research needs in this field.
Conclusion:
The scientific credibility of an international expert report may be at stake if its recommendations do not rely on sound objective research findings and a comprehensive review of the existing literature. The critical comments in this study will certainly help improve the present WHO report.</description>
        <link>http://www.jnrbm.com/content/5/1/17</link>
                <dc:creator>Kamal Chaouachi</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2006, null:17</dc:source>
        <dc:date>2006-11-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-5-17</dc:identifier>
                                <prism:require>/content/figures/1477-5751-5-17-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2006-11-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/11/1/11">
        <title>Lifestyle counselling during pregnancy and offspring weight development until four years of age: follow-up study of a controlled trial

</title>
        <description>Background:
Fetal conditions are known to be partly responsible for the child&apos;s risk for obesity. Our pilot study aimed to determine the effect of gestational lifestyle counseling on the offspring weight gain until 4 years of age and to estimate power for future studies.Design and methodsFirst-time pregnant mothers participated in a controlled trial conducted in maternity health clinics during 2004 - 2006. The intervention included individual counseling on physical activity and diet, and an option to attend supervised group exercise sessions. The participant mothers (N = 109) received a follow-up questionnaire concerning 13 repeated growth measurements of their offspring. Response rate to the follow-up questionnaire was 66.1% (N = 72/109).
Results:
The increase of BMI z-score between 24 - 48 months was not significantly slower among the intervention group offspring (95% CI -0.025 to 0.009, p = 0.34) compared to control group. Z-scores for weight-for-length/height did not differ between groups when the period 0 - 48 months was analyzed (95% CI -0.010 to 0.014, p = 0.75).
Conclusions:
In this pilot study gestational lifestyle counseling did not significantly slow the weight gain of the offspring. Gestational intervention studies with at least 300 mothers per group are needed to confirm the possible effect on offspring&apos;s risk for obesity.Trial registrationCurrent Controlled Trials ISRCTN21512277.</description>
        <link>http://www.jnrbm.com/content/11/1/11</link>
                <dc:creator>Taina Mustila</dc:creator>
                <dc:creator>Jani Raitanen</dc:creator>
                <dc:creator>Päivi Keskinen</dc:creator>
                <dc:creator>Antti Saari</dc:creator>
                <dc:creator>Riitta Luoto</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2012, null:11</dc:source>
        <dc:date>2012-05-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-11-11</dc:identifier>
                                <prism:require>/content/figures/1477-5751-11-11-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2012-05-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/11/1/10">
        <title>Protein kinase A enhances lipopolysaccharide-induced IL-6, IL-8, and PGE2 production by human gingival fibroblasts.</title>
        <description>ObjectivePeriodontal disease is accompanied by inflammation of the gingiva and destruction of periodontal tissues, leading to alveolar bone loss in severe clinical cases. Interleukin (IL)-6, IL-8, and the chemical mediator prostaglandin E2 (PGE2) are known to play important roles in inflammatory responses and tissue degradation.Recently, we reported that the protein kinase A (PKA) inhibitor H-89 suppresses lipopolysaccharide (LPS)-induced IL-8 production by human gingival fibroblasts (HGFs). In the present study, the relevance of the PKA activity and two PKA-activating drugs, aminophylline and adrenaline, to LPS-induced inflammatory cytokines (IL-6 and IL-8) and PGE2 by HGFs were examined.
Methods:
HGFs were treated with LPS from Porphyromonas gingivalis and H-89, the cAMP analog dibutyryl cyclic AMP (dbcAMP), aminophylline, or adrenaline. After 24 h, IL-6, IL-8, and PGE2 levels were evaluated by ELISA.
Results:
H-89 did not affect LPS-induced IL-6 production, but suppressed IL-8 and PGE2 production. In contrast, dbcAMP significantly increased LPS-induced IL-6, IL-8, and PGE2 production. Up to 10 &#956;g/ml of aminophylline did not affect LPS-induced IL-6, IL-8, or PGE2 production, but they were significantly increased at 100 &#956;g/ml. Similarly, 0.01 &#956;g/ml of adrenaline did not affect LPS-induced IL-6, IL-8, or PGE2 production, but they were significantly increased at concentrations of 0.1 and 1 &#956;g/ml. In the absence of LPS, H-89, dbcAMP, aminophylline, and adrenaline had no relevance to IL-6, IL-8, or PGE2 production.
Conclusion:
These results suggest that the PKA pathway, and also PKA-activating drugs, enhance LPS-induced IL-6, IL-8, and PGE2 production by HGFs. However, aminophylline may not have an effect on the production of these molecules at concentrations used in clinical settings (8 to 20 &#956;g/ml in serum). These results suggest that aminophylline does not affect inflammatory responses in periodontal disease.</description>
        <link>http://www.jnrbm.com/content/11/1/10</link>
                <dc:creator>Toshiaki Ara</dc:creator>
                <dc:creator>Yoshiaki Fujinami</dc:creator>
                <dc:creator>Hiroko Urano</dc:creator>
                <dc:creator>Kaname Hirai</dc:creator>
                <dc:creator>Toshimi Hattori</dc:creator>
                <dc:creator>Hiroo Miyazawa</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2012, null:10</dc:source>
        <dc:date>2012-03-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-11-10</dc:identifier>
                            <dc:title>Aminophylline does not exacerbate periodontal disease</dc:title>
                            <dc:description>Commonly prescribed for bronchial disorders, aminophylline does not adversely affect inflammatory response and exacerbate symptoms in periodontal disease at concentrations used in clinical settings unlike other PKA-inhibiting drugs.</dc:description>
                <prism:require>/content/figures/1477-5751-11-10-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2012-03-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/5/1/1">
        <title>The Mayer-Rokitansky-Kuster-Hauser syndrome (congenital absence of uterus and vagina) - phenotypic manifestations and genetic approaches</title>
        <description>The Mayer-Rokitansky-K&#252;ster-Hauser (MRKH) syndrome affects at least 1 out of 4500 women and has for a long time been considered as a sporadic anomaly. Congenital absence of upper vagina and uterus is the prime feature of the disease which, in addition, is often found associated with unilateral renal agenesis or adysplasia as well as skeletal malformations (MURCS association). The phenotypic manifestations of MRKH overlap various other syndromes or associations and thus require accurate delineation. Since MRKH manifests itself in males, the term GRES syndrome (Genital, Renal, Ear, Skeletal) might be more appropriate when applied to both sexes. The MRKH syndrome, when described in familial aggregates, seems to be transmitted as an autosomal dominant trait with an incomplete degree of penetrance and variable expressivity. This suggests the involvement of either mutations in a major developmental gene or a limited chromosomal deletion. Until recently progress in understanding the genetics of MRKH syndrome has been slow, however, now HOX genes have been shown to play key roles in body patterning and organogenesis, and in particular during genital tract development. Expression and/or function defects of one or several HOX genes may account for this syndrome.</description>
        <link>http://www.jnrbm.com/content/5/1/1</link>
                <dc:creator>Daniel Guerrier</dc:creator>
                <dc:creator>Thomas Mouchel</dc:creator>
                <dc:creator>Laurent Pasquier</dc:creator>
                <dc:creator>Isabelle Pellerin</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2006, null:1</dc:source>
        <dc:date>2006-01-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-5-1</dc:identifier>
                                <prism:require>/content/figures/1477-5751-5-1-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2006-01-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/11/1/1">
        <title>The female menstrual cycle does not influence testosterone concentrations in male partners</title>
        <description>Background:
The time of ovulation has since long been believed to be concealed to male heterosexual partners. Recent studies have, however, called for revision of this notion. For example, male testosterone concentrations have been shown to increase in response to olfactory ovulation cues, which could be biologically relevant by increasing sexual drive and aggressiveness. However, this phenomenon has not previously been investigated in real-life human settings. We therefore thought it of interest to test the hypothesis that males&apos; salivary testosterone concentrations are influenced by phases of their female partners&apos; menstrual cycle; expecting a testosterone peak at ovulation.
Methods:
Thirty young, healthy, heterosexual couples were recruited. During the course of 30-40 days, the women registered menses and ovulation, while the men registered sexual activity, physical exercise, alcohol intake and illness (confounders), and obtained daily saliva samples for testosterone measurements. All data, including the registered confounders, were subjected to multiple regression analysis.
Results:
In contrast to the hypothesis, the ovulation did not affect the testosterone levels, and the resulting testosterone profile during the menstrual cycle was on the average flat. The specific main hypothesis, that male testosterone levels on the day of ovulation would be higher than day 4 of the cycle, was clearly contradicted by a type II error(&#946;)-analysis (&lt; 14.3% difference in normalized testosterone concentration; &#946; = 0.05).
Conclusions:
Even though an ovulation-related salivary testosterone peak was observed in individual cases, no significant effect was found on a group level.</description>
        <link>http://www.jnrbm.com/content/11/1/1</link>
                <dc:creator>Jakob Strom</dc:creator>
                <dc:creator>Edvin Ingberg</dc:creator>
                <dc:creator>Emma Druvefors</dc:creator>
                <dc:creator>Annette Theodorsson</dc:creator>
                <dc:creator>Elvar Theodorsson</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2012, null:1</dc:source>
        <dc:date>2012-01-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-11-1</dc:identifier>
                            <dc:title>Menstrual cyle does not affect male testosterone levels</dc:title>
                            <dc:description>The hypothesis that male testosterone concentrations increase with female olfactory ovulation cues is contradicted in a study which monitored thirty couples and established no significant effect, also suggesting no relevance of ovulation to male sexual drive and aggressiveness.</dc:description>
                <prism:require>/content/figures/1477-5751-11-1-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-01-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/11/1/12">
        <title>In vitro studies of the influence of glutamatergic agonists on the Na+,K+-ATPase and K+-p-nitrophenylphosphatase activities in the hippocampus and frontal cortex of rats</title>
        <description>Background:
The overstimulation of excitatory glutamatergic neurotransmission and the inhibition of Na+,K+-ATPase enzymatic activity have both been implicated in neurotoxicity and are possibly related to the pathogenesis of epilepsy and neurodegenerative disorders. In the present study, we investigated whether glutamatergic stimulation by the glutamatergic agonists glutamate, alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) modulates the Na+,K+-ATPase and the K+-p-nitrophenylphosphatase activities in the crude synaptosomal fraction of the hippocampus and the frontal cortex of rats. Results: Our results demonstrated that these glutamatergic agonists did not influence the activities of Na+,K+-ATPase or K+-p-nitrophenylphosphatase in the brain structures analyzed. Assays with lower concentrations of ATP to analyze the preferential activity of the Na+,K+-ATPase isoform with high affinity for ATP did not show any influence either. Conclusions: These findings suggest that under our experimental conditions, the stimulation of glutamatergic receptors does not influence the kinetics of the Na+,K+-ATPase enzyme in the hippocampus and frontal cortex.</description>
        <link>http://www.jnrbm.com/content/11/1/12</link>
                <dc:creator>Marcos Contó</dc:creator>
                <dc:creator>Marco Venditti</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2012, null:12</dc:source>
        <dc:date>2012-05-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-11-12</dc:identifier>
                            <dc:title>Glutamatergic stimulation does not influence enzymatic activity</dc:title>
                            <dc:description>A better understanding is needed of the relationship between glutamatergic activation and enzymatic activity, suggests this study which finds that glutamatergic stimulation in rats does not influence Na+,K+-ATPase activity in the frontal lobe, the inhibition of which is associated with pathogenesis of epilepsy.</dc:description>
                <prism:require>/content/figures/1477-5751-11-12-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2012-05-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/5/1/16">
        <title>Searching for plasticity in dissociated cortical cultures on multi-electrode arrays</title>
        <description>We attempted to induce functional plasticity in dense cultures of cortical cells using stimulation through extracellular electrodes embedded in the culture dish substrate (multi-electrode arrays, or MEAs). We looked for plasticity expressed in changes in spontaneous burst patterns, and in array-wide response patterns to electrical stimuli, following several induction protocols related to those used in the literature, as well as some novel ones. Experiments were performed with spontaneous culture-wide bursting suppressed by either distributed electrical stimulation or by elevated extracellular magnesium concentrations as well as with spontaneous bursting untreated. Changes concomitant with induction were no larger in magnitude than changes that occurred spontaneously, except in one novel protocol in which spontaneous bursts were quieted using distributed electrical stimulation.</description>
        <link>http://www.jnrbm.com/content/5/1/16</link>
                <dc:creator>Daniel Wagenaar</dc:creator>
                <dc:creator>Jerome Pine</dc:creator>
                <dc:creator>Steve Potter</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2006, null:16</dc:source>
        <dc:date>2006-10-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-5-16</dc:identifier>
                                <prism:require>/content/figures/1477-5751-5-16-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2006-10-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/9/1/8">
        <title>Shortcomings of short hairpin RNA-based transgenic RNA interference in mouse oocytes</title>
        <description>Background:
RNA interference (RNAi) is a powerful approach to study a gene function. Transgenic RNAi is an adaptation of this approach where suppression of a specific gene is achieved by expression of an RNA hairpin from a transgene. In somatic cells, where a long double-stranded RNA (dsRNA) longer than 30 base-pairs can induce a sequence-independent interferon response, short hairpin RNA (shRNA) expression is used to induce RNAi. In contrast, transgenic RNAi in the oocyte routinely employs a long RNA hairpin. Transgenic RNAi based on long hairpin RNA, although robust and successful, is restricted to a few cell types, where long double-stranded RNA does not induce sequence-independent responses. Transgenic RNAi in mouse oocytes based on a shRNA offers several potential advantages, including simple cloning of the transgenic vector and an ability to use the same targeting construct in any cell type.
Results:
Here we report our experience with shRNA-based transgenic RNAi in mouse oocytes. Despite optimal starting conditions for this experiment, we experienced several setbacks, which outweigh potential benefits of the shRNA system. First, obtaining an efficient shRNA is potentially a time-consuming and expensive task. Second, we observed that our transgene, which was based on a common commercial vector, was readily silenced in transgenic animals.
Conclusions:
We conclude that, the long RNA hairpin-based RNAi is more reliable and cost-effective and we recommend it as a method-of-choice when a gene is studied selectively in the oocyte.</description>
        <link>http://www.jnrbm.com/content/9/1/8</link>
                <dc:creator>Lenka Sarnova</dc:creator>
                <dc:creator>Radek Malik</dc:creator>
                <dc:creator>Radislav Sedlacek</dc:creator>
                <dc:creator>Petr Svoboda</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2010, null:8</dc:source>
        <dc:date>2010-10-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-9-8</dc:identifier>
                                <prism:require>/content/figures/1477-5751-9-8-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2010-10-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/11/1/7">
        <title>Clinical predictors of inflammatory bowel disease in a genetically well-defined Caucasian population </title>
        <description>Background:
Crohn&apos;s disease (CD) and ulcerative colitis (UC), the two main types of inflammatory bowel disease (IBD), are multifactorial conditions of unknown etiology. The objective of this study is to examine the combined gene-environment interactions influencing IBD susceptibility in a well-defined Caucasian cohort in rural mid-America.
Methods:
Patients were diagnosed to have CD or UC using conventional radiologic, endoscopic, and/or histopathologic findings. Histological diagnosis was made by a single specialist gastrointestinal pathologist with a particular interest in IBD. Information regarding cigarette smoke exposure was obtained by administration of the Behavioral Risk Factor Surveillance System Survey (BRFSS) to all patients. Genomic DNA was extracted from peripheral blood leukocytes, and polymerase chain reaction (PCR) amplification and genotyping were performed for 11 Single Nucleotide Polymorphisms (SNP) in NOD2, IL23r, OCTN1 genes along with IGR.
Results:
Our cohort consists of 1196 patients: 435 controls, 485 CD patients, and 276 UC patients. Only patients with genotype data for at least 7 of 11 SNPs were included in our data analysis. The control groups for all 11 SNPs were in Hardy-Weinberg Equilibrium. In genotype-association SNP analysis, all NOD2 SNPs (rs5743293, rs2066844, rs2066845) and the IL23r SNP (rs11465804) showed a significant association to IBD (p &lt; 0.03). A multiple gene-interaction analysis showed an association between NOD2 and IL23r with UC (p = 0.04). There were no associations between any OCTN1 and IGR SNPs and IBD in this cohort. A multivariable logistic regression analysis showed that female gender, &quot;current&quot; or &quot;former&quot; smoking status, family history of IBD, and NOD2 SNP minor alleles were associated with CD.
Conclusion:
IBD remains to be challenging to properly diagnose, characterize, and treat. Our study proposes a combined genetic, phenotypic, and environmental approach in an attempt to better understand IBD. Previously demonstrated associations between OCTN1 and IGR and IBD were not confirmed.</description>
        <link>http://www.jnrbm.com/content/11/1/7</link>
                <dc:creator>Ziad Kanaan</dc:creator>
                <dc:creator>Maurice Eichenberger</dc:creator>
                <dc:creator>Surriya Ahmad</dc:creator>
                <dc:creator>Clayton Weller</dc:creator>
                <dc:creator>Henry Roberts</dc:creator>
                <dc:creator>Jianmin Pan</dc:creator>
                <dc:creator>Shesh Rai</dc:creator>
                <dc:creator>Robert Petras</dc:creator>
                <dc:creator>E.Brooks Weller</dc:creator>
                <dc:creator>Susan Galandiuk</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2012, null:7</dc:source>
        <dc:date>2012-01-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-11-7</dc:identifier>
                                <prism:require>/content/figures/1477-5751-11-7-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2012-01-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/8/1/3">
        <title>Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study</title>
        <description>Background:
Vardenafil (Levitra&#174;) represents a potent and highly selective phosphodiesterase type 5 (PDE5) inhibitor, which is established for treatment of various diseases. There are several unpublished reports from patients stating that vardenafil has a considerable therapeutic effect on their concomitant tinnitus. This pilot study was conducted to specifically assess the effect of vardenafil in patients with chronic tinnitus.
Methods:
This trial was based on a prospective, randomized, double-blind, placebo-controlled, parallel group design. Fourty-two consecutive subjects with mon- or binaural chronic tinnitus received 10 mg vardenafil (N = 21) or matching placebo tablets (N = 21) administered orally twice a day over a period of 12 weeks. Clinical examination and data acquisition took place at each visit: at baseline, after 4 weeks, after 12 weeks (end of treatment with study medication), and at non-medicated follow-up after 16 weeks. Assessment of clinical effectiveness was based on a standardized tinnitus questionnaire (TQ), the Short Form 36 health survey (SF-36), audiometric measurements (mode, pitch and loudness of tinnitus; auditory thresholds) and biomarkers of oxidative stress in patients&apos; blood (malondialdehyde, protein carbonyl, homocysteine and total antioxidative status). Therapeutic efficacy was evaluated by comparison of subjective and objective parameters with baseline data between both treatment groups (ANCOVA).
Results:
Vardenafil had no superior efficacy over placebo in the treatment of chronic tinnitus during this study. The primary efficacy criterion &apos;TQ total score&apos; failed to demonstrate significant improvement compared to placebo. Subjective reports of TQ subscales and general quality of life areas (SF-36), objective audiometric examinations as well as investigated biomarkers for oxidative stress did not reveal any significant treatment effects. The safety profile was favorable and consistent with that in other vardenafil studies.
Conclusion:
Although hypoxia and ischemia play a special role in the pathogenesis of tinnitus, the PDE5-inhibitor-induced increase of nitric oxide-mediated vasodilatation exerted no specific influence on tinnitus symptomatology. Considering the unclear risk of rarely associated hearing impairment, systemic application of vardenafil or other PDE5 inhibitors prove to be not appropriate for therapy of chronic tinnitus.</description>
        <link>http://www.jnrbm.com/content/8/1/3</link>
                <dc:creator>Birgit Mazurek</dc:creator>
                <dc:creator>Heidemarie Haupt</dc:creator>
                <dc:creator>Agnieszka Szczepek</dc:creator>
                <dc:creator>Joerg Sandmann</dc:creator>
                <dc:creator>Johann Gross</dc:creator>
                <dc:creator>Burghard Klapp</dc:creator>
                <dc:creator>Holger Kiesewetter</dc:creator>
                <dc:creator>Ulrich Kalus</dc:creator>
                <dc:creator>Timo Stover</dc:creator>
                <dc:creator>Philipp Caffier</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2009, null:3</dc:source>
        <dc:date>2009-02-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-8-3</dc:identifier>
                                <prism:require>/content/figures/1477-5751-8-3-toc.gif</prism:require>
                <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2009-02-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

